Shire Pharmaceuticals "hold"

12/06/05 - ING Financial Markets

LONDON, December 6 (newratings.com) - Analysts at ING Financial Markets maintain their "hold" rating on Shire Pharmaceuticals (SHP-GBX). The 12-month target price is set to 650p.

In a research note published this morning, the analysts mention that Shire Pharmaceuticals has undertaken several initiatives, such as the acquisition of TKT and the in-licensing of NRP104, in order to address the competitive threat posed by Barr Pharmaceutical’s generic version of Adderall XR. The company expects to receive the US approval for the ADHD patch, Daytrana, before end-2005.